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Background: Naturally expressed mouse (m) 6*-nAChRs have negligible functional expression in vitro.
Results: Functional expression of mouse 623- or 643-nAChRs is enhanced uponmanipulation of 3 subunit N-termi-
nal extracellular domain residues.
Conclusion: N-terminal extracellular domains in nAChR 3 subunits play heretofore underappreciated roles in controlling
functional expression of 6*-nAChR.
Significance: nAChR “accessory” subunits are critical elements in nAChR assembly and function.
Functional heterologous expression of naturally expressed
mouse 6*-nicotinic acetylcholine receptors (m6*-nAChRs;
where “*” indicates the presence of additional subunits) has
been difficult. Here we expressed and characterized wild-type
(WT), gain-of-function, chimeric, or gain-of-function chimeric
nAChR subunits, sometimes as hybrid nAChRs containing both
human (h) andmouse (m) subunits, in Xenopus oocytes. Hybrid
m6m4h3- (5–8-fold) or WT m6m4m3-nAChRs
(2-fold) yielded higher function than m6m4-nAChRs.
Function was not detected when m6 and m2 subunits were
expressed together or in the additional presence of h3 or m3
subunits. However, function emerged upon expression of
m6m2m3V9S-nAChRs containing3 subunits having gain-
of-function V9S (valine to serine at the 9-position) mutations
in transmembrane domain II and was further elevated 9-fold
when h3V9S subunits were substituted for m3V9S subunits.
Studies involving WT or gain-of-function chimeric mouse/hu-
man 3 subunits narrowed the search for domains that influ-
ence functional expression of m6*-nAChRs. Using h3 sub-
units as templates for site-directed mutagenesis studies,
substitution with m3 subunit residues in extracellular N-ter-
minal domain loops “C” (Glu221 and Phe223), “E” (Ser144 and
Ser148), and “2-3” (Gln94 and Glu101) increased function of
m6m2*- (2–3-fold) or m6m4* (2–4-fold)-nAChRs.
EC50 values for nicotine acting at m6m4*-nAChR were unaf-
fected by 3 subunit residue substitutions in loop C or E. Thus,
amino acid residues located in primary (loop C) or comple-
mentary (loops 2-3 and E) interfaces of 3 subunits are
some of themolecular impediments for functional expression
of m6m23- or m6m43-nAChRs.
Nicotinic acetylcholine receptors (nAChRs)2 are a diverse set
of pentameric, transmembrane, signal-transducing proteins
found in the nervous system and elsewhere. Vertebrate nAChR
subunits 1–10, 1–4, , , and  are encoded from a family
of distinct genes. 1, 1, , and either  or  subunits form
muscle-type nAChRs, and other nAChR subtypes are formed as
heteromers or homomers of the remaining subunits (1). Homo-
meric 7-nAChRs and heteromeric 42- or 62*-nAChRs
(* indicates the known or possible presence of additional sub-
units) are the dominant subtypes in the central nervous system
(CNS) (2). 64*-nAChRs do not seem to be abundant in the
rodent CNS but are found in rat dorsal root ganglion neurons
and in human adrenal chromaffin cells (3, 4). 6*-nAChRs
seem to participate in the modulation of dopamine release,
locomotion, reward, and reinforcement and have been impli-
cated in schizophrenia and Parkinson disease (5–12).
Beyond the known formation of 62- or 64-nAChRs (3,
4, 13–15), integration of nAChR 4, 3, or 5 subunits can
occur (14–17) to yield more complex 6*-nAChR subtypes.
nAChR 3 or 5 subunits have been classified as “accessory”
subunits because they donot form functional receptors alone or
seem to combine with any other single kind of nAChR  or 
subunit in a functional way, but they can participate in trinary
complexes containing other, selected  and  subunits (15,
18–22). Integration of nAChR 3 subunits in the accessory
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grant R01DA012844 andDA026356 (toM. D. L.) andDA015389 (to R. J. L.).
This work was also supported by endowment and capitalization funds
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Research Program of Philip Morris USA Inc. and Philip Morris International
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Dash, B., Bhakta, M., Whiteaker, P., Stitzel, J. A., Chang, Y., and Lukas, R. J.
(2009) Gain-of-function mutants in human or mouse nAChR 3 subunits
interchangeably activate either human or mouse 64*-nAChR but not
human or mouse 62*-nAChR. Soc. Neurosci. Abstr. 35, 34.7.
1 Towhomcorrespondence shouldbeaddressed:DivisionofNeurobiology, Bar-
row Neurological Inst., 350 W. Thomas Rd., Phoenix, AZ 85013. Tel.: 602-406-
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position is suggested to be a critical, final step in formation,
assembly, and stability of mature 63*-nAChRs (6, 23) and is
important for function of 6*- and other nAChRs (24–31). A
positive role of the 3 subunit, rather than a negative role (27),
in the function of 6*-nAChRs has been revealed from knock-
out animal studies (6). However, structure-function relation-
ships and pharmacological features of 6*-nAChRs are poorly
understood because receptors thought to exist naturally have
not been easily recreated in heterologous expression systems
(13–15, 20).
There have been some successes in expressing functional
6*-nAChRs using Xenopus oocytes (22) or cell lines when a
chimeric nAChR (6/3) subunit (composed of the 6 subunit
extracellular N-terminal domain fused to an otherwise 3 sub-
unit) was used instead of the wild-type (WT) nAChR 6 sub-
unit (32) or when enhanced GFP-tagged 6- and 2-nAChR
subunits were coexpressed in Neuro-2a cells (13). Other strat-
egies have been to use gain-of-function variants of 3 or 5
subunits (typically using subunits mutated to express serine
instead of valine at the so-called 9-position in the subunit
channel-lining, second transmembrane domain (TM II); V9S)
to express functional 6*-nAChRs in Xenopus oocytes (15, 27).
We also recently succeeded in producing functional, hybrid
63*-nAChRs substituting mouse (m) 6 subunits for human
(h) 6 subunits to express functional m6h4h3- or
m6h2h3V9S-nAChRs (15). This kind of study leveraging
innate variations in amino acid (AA) residues between subunits
from different species produced valuable information regard-
ing structure and function of invertebrate and vertebrate
nAChRs (15, 21, 33, 34).
Here we report that nAChR h3 or h3V9S (i.e. h3(V273S))
subunits coexpressed in oocytes also expressing m6 subunits
in the presence of m4 or m2 subunits yielded nAChRs with
higher levels of function than those of m6m4m3- or
m6m2m3V9S-nAChRs. Further studies using chimeric or
gain-of-function chimeric mouse/human nAChR 3 subunits
and site-directed mutagenesis identified AA residues in the
extracellular N-terminal domain (NTD; in so-called loops “2-
3,” C, and E) of m3 subunits that when substituted with cor-
responding residues from h3 subunits alone or in some spe-
cific combinations increased the function of m6m2*- and
m6m4*-nAChRs. These studies elucidate some of the struc-
tural bases dictating roles for nAChR 3 subunits in functional
expression of m6m2*- and m6m4*-nAChRs.
EXPERIMENTAL PROCEDURES
Bioinformatics and Homology Modeling—Using several
Web-available threadingmethods, the1 subunit of themuscle
nicotinic acetylcholine receptor of the marbled electric ray
(Torpedo marmorata) (2BG9.B; Protein Data Bank code 2BG9
Chain B) (35) was identified as a suitable template for three-
dimensional modeling of m3 subunits (SWISS-MODEL Pro-
tein Modeling Server) (36). The overall stereochemical quality
of the final model was assessed by the program PROCHECK
(37). The homology model for the nAChRm3 subunit was ren-
dered using UCSF Chimera, a program for interactive visualiza-
tion and analysis of molecular structures. Protein sequences for
nAChR 3 subunits of several species or mouse nAChR subunits
retrieved fromtheNationalCenter forBiotechnology Information
(NCBI) EntrezWeb servicewere alignedwith eachotherusing the
Web programClustalW.
Chemicals—All chemicals for electrophysiology were obtained
from Sigma. Fresh agonist (acetylcholine (ACh) or nicotine) or
antagonist (atropine) stock solutions were made daily or diluted
from frozen stock in Ringer’s solution (OR2), which consisted of
92.5 mMNaCl, 2.5 mM KCl, 1 mM CaCl2, 1 mMMgCl2, and 5 mM
HEPES, pH 7.5.
Wild-type nAChR Subunits—nAChR h3, m6, m2, m3,
and m4 subunits were subcloned into the oocyte expression
vector pGEMHE as described previously (19, 30).
nAChR 3 Subunit Chimeras—Guided by an alignment of
nAChR h3 and m3 subunit protein sequences (see Fig. 1A),
chimericmouse/human3 subunits were designed and created
(see Fig. 1B) as described below. We cared to construct chime-
ras in amanner that isolated domains and/or structural features
in 3 subunits.
Construction of the m3(1–187)/h3(182–458) Chimeric
Subunit (SalI Site-based Construct)—Mouse nAChR 3 sub-
units possess an innate SalI restriction site (see Fig. 1) in the
NTD aroundAA residue Val187. A SalI restriction site (Table 1)
TABLE 1
Primers and restriction sites used to create mutant/chimeric constructs
For mutants, the first amino acid (single letter code; numbering begins at the translation start methionine) designates the wild-type nAChR (human or mouse) subunit
residue that is replaced with the indicated second amino acid. In the forward primer nucleic acid sequence, capitalization indicates the nucleotide(s) changed from the
wild-type subunit to create the corresponding mutant or restriction site.
Primer Mutant Forward primer sequences
P1 h3_V181_SalI 5-cttatgatggcaccatggtCgacctcattttgatcaatg-3
m3_Val187_SalI Innate
m3_BglII Innate
h3_BglII Innate
P2 m3_R375_BsiWI 5-gagagtaagggaaccgtACgggggaaatttccaggg-3
P3 h3_K369_BsiWI 5-ccagagaaagaggagagtcaaccagtCgtACGaggcaaagtcctcgaaaaaaagaaac-3
P4 m3 (V279S)a 5-cacctcggttttgTCttctttgacagtg-3
P5 h3 (V273S)a 5-cattatccacatcggtcttgTCttctctgacagttttcc-3
P6 m3 (Q94H) 5-caggaatggacagaccaTaaattacgatggaatccc-3
P7 m3 (E101D) 5-caaaaattacgatggaatcccgaTgactatggtggaattaattcg-3
P8 m3 (N107H) 5-ccgaagactatggtggaattCattcgataaaggttccatc-3
P9 m3 (Q94H/E101D) 5-caTaaattacgatggaatcccgaTgactatggtggaattaattcg-3
m3 (Q94H/N107H) Use P8 on nAChR m3 (Q94H) construct
P10 m3 (S144N/S148V) 5-ctcatgaccaaggccattgtgaaatccaAcggaaccgtcGgttggactcctcccgccagctacaaaag-3
P11 m3 (E221D) 5-gaagggcaacagaagagaCggcttttactcctatccg-3
P12 m3 (E221D/F223V) 5-gggatgaagggcaacagaagagaCggcGtttactcctatccgtttgttacc-3
a Primer created and used before (15).
Effects of3 Subunits onMouse6*-nAChR Function
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was created in the pGEMHE-h3 construct (i.e. pGEMHE-
h3(SalI)) by site-directed mutagenesis around AA residue
Val181 by using primers P1 (forward) and its reverse comple-
ment (RC) (Table 1). Both pGEMHE-m3 and pGEMHE-
h3(SalI) constructs were digested with SalI and XbaI where
the XbaI site is located downstream of the sequence encoding
the C-terminal end of the m3 or h3 cDNA and is in the
multiple cloning site. The pGEMHE-m3(XbaISalI) (i.e.
m3(1–187)) and h3(SalIXbaI) (i.e. h3(182–458)) cDNA
fragments were gel-purified and ligated, producing a chimeric
cDNA construct pGEMHE-m3(1–187)/h3(182–458) (i.e.
m3(Met1–Val187)/h3(Asp182–His458)) (see Fig. 1).
Construction of the m3(1–329)/h3(324–458) Chimera
(BglII Site-based Construct)—Both human and mouse 3 sub-
units possess an innate BglII restriction site right after the third
transmembrane domain (TM III). The BglII site allows cutting
through human andmouse 3 cDNA at equivalent and homol-
ogous residues (see Fig. 1). Both pGEMHE-m3 and pGEMHE-
h3 plasmids were double digested with BglII and XbaI.
pGEMHE-m3(XbaIBglII) (i.e.m3(1–329)) and h3(BglII-
XbaI) (i.e. h3(324–458)) cDNA fragments were gel-purified
and ligated to produce the chimeric construct pGEMHE-
m3(1–329)/m3(324–458) (i.e. m3(Met1–Arg329)/h3(Ser324–
His458)) (see Fig. 1). This chimera could be considered as a
combination of theNTDofm3 subunit and the rest of the h3
subunit because the AA residues between the 239th residue
(presumably its N-terminal end) and the BglII site in the m3
subunit are identical to those between the 233rd residue (pre-
sumably its N-terminal end) and the BglII site in the h3 sub-
unit (see Fig. 1).
Construction of the m3(1–375)/h3(370–458) Chimera
(BsiWI Site-based Construct)—A BsiWI restriction site around
AA residue Arg375 in pGEMHE-m3 (using P2 and its RC;
Table 1) and another one around AA residue Lys369 in
pGEMHE-h3 (using P3 and its RC) were created by site-di-
rectedmutagenesis (Table 1). Both pGEMHE-m3(BsiWI) and
pGEMHE-h3(BsiWI) plasmids were double digested with
BsiWI and XbaI. pGEMHE-m3(XbaIBsiWI) (i.e. m3(1–
375)) and h3(BsiWIXbaI) (i.e. h3(370–458)) cDNA frag-
ments were gel-purified and ligated to produce the chimeric
pGEMHE-m3(1–375)/h3(370–458) (i.e. m3(Met1–Arg375)/
h3(Gly370–His458)) (see Fig. 1).
Gain-of-function Chimeric nAChR 3 Subunits—TM II 9
valine-to-serine (V9S) mutations in pGEMHE-m3(1–329)/
h3(324–458) and pGEMHE-m3(1–375)/h3(370–458)
constructs were introduced using primer P4 (Table 1) and its
RC to produce pGEMHE-m3(1–329)V279S/h3(324–458)
and pGEMHE-m3(1–375)V279S/h3(370–458) constructs,
respectively (Fig. 1). Similarly, TM II V9S mutations in the
pGEMHE-m3(1–187)/h3(182–458) construct were intro-
duced using primer P5 (Table 1) and its RC to produce the
pGEMHE-m3(1–187)/h3(182–458)V273S construct.
PointMutants—TMIIV9S, L9S, orV13Smutations in h3
(V9S  V273S; V13S  V277S), m3 (V9S  V279S;
V13SV283S), or m6 (L9S L280S; V13SV284S) sub-
units were introduced into the pGEMHE background using the
QuikChange II site-directed mutagenesis kit (Stratagene, La
Jolla, CA) as described previously (15, 38).
Single or double mutations in nAChR m3 subunit (i.e.
Q94H, E101D, N107H, Q94H/E101D, S144N/S158V, E221D,
and E221D/F223V) were introduced using the QuikChange II
site-directed mutagenesis kit using their respective forward
(P6, P7, P8, P9, P10, P11, and P12; Table 1) andRCprimers. The
pGEMHE-m3(Q94H/N107H) construct was made by site-di-
rected mutagenesis of the pGEMHE-m3(Q94H) construct
using primer P8 and its RC.
TM II 9 valine-to-serine mutations in plasmids encoding
m3(Q94H), m3(E101D), m3(N107H), m3(Q94H/E101D),
m3(Q94H/N107H), m3(S144N/S158V), m3(E221D), or
m3(E221D/F223V) subunits were introduced using primer P4
(Table 1) and its RC. Construct integrity and accuracy of all sub-
units were confirmed by DNA sequencing.
Complementary RNA (cRNA) Preparation—All pGEMHE
plasmids were linearized immediately downstream of the
3-polyadenylation sequence. NheI was used to linearize h3,
h3V9S, h3V13S, m6, m6L9S, m6V13S, m2, m3V9S,
m4, m3(1–187)/h3(182–458), m3(1–329)/h3(324–458),
m3(1–375)/h3(370–458), m3(1–187)/h3(182–458)V273S,
m3(1–329)V279S/h3(324–458), m3(1–375)V279S/h3(370-
458), m3(Q94H), m3(E101D), m3(N107H), m3(Q94H/
E101D), m3(Q94H/N107H), m3(S144N/S158V), m3(E221D),
m3(E221D/F223V), m3(Q94H)V9S, m3(E101D)V9S, m3-
(N107H)V9S, m3(Q94H/E101D)V9S, m3(Q94H/N107H)V9S,
m3(S144N/S158V)V9S, m3(E221D)V9S, and m3(E221D/
F223V)V9S subunit-encoding plasmids. Capped, full-length
cRNAs were prepared using individual reaction components as
detailed earlier (19) or using the mMESSAGE mMACHINE
T7 kit (Ambion Inc./Invitrogen) following the manufacturer’s
instructions. The integrity and quality of the cRNAs were
checked by electrophoresis and UV spectroscopy prior to
cRNA injection.
Preparation of cRNA Mixtures for Injection—We planned to
introduce identical amounts of cRNA, presumably producing
equal amounts of each subunit protein, into oocytes largely due
to lack of information about the levels of mRNA for each sub-
unit that composes 6*-nAChRs in neurons or cells. We provi-
sionally assumed that 6 subunits or their mutants in associa-
tion with 2 or 4 subunits would form complexes having 2:3
and/or 3:2 ratios of the indicated subunits and that oocytes also
injected with WT, chimeric, or other forms of 3 subunits
would express nAChR with 2:2:1 ratios of ::3 subunits. For
expression of binary nAChRs (i.e. nAChRs containing two sub-
units;    but not 3), cRNA mixtures were prepared by
mixing 1 l of cRNA for each subunit and an additional micro-
liter of RNase-free water (i.e. total volume, 3 l). Similarly, for
expression of trinary nAChRs (i.e. nAChRs containing three
subunits; ( ) 3) cRNAmixtures were prepared bymix-
ing 1 l of cRNA for each subunit. Several preparations of each
cRNA mixture were prepared and stored at 80 °C until fur-
ther use.
cRNA concentrations for each nAChR  and  subunit were
adjusted to 150 ng/l for the first set of experiments (for data
presented in Table 2 and Fig. 2). As noted above, introduction
of 69 nl of cRNAs (from a 3-l cRNAmixture) into each oocyte
would deliver 3.5 ng of cRNA for each  and  subunit
whether binary or trinary nAChRs are expressed. For all other
Effects of3 Subunits onMouse6*-nAChR Function
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experiments, concentrations of cRNAs prepared for each
nAChR and subunit were adjusted to 500 ngl1. Injection
of 138 nl of cRNA of a 3-l cRNA mixture into each oocyte
would deliver 23 ng of cRNAs for each  and  subunit
whether binary or trinary nAChRs are expressed.
Oocyte Preparation and cRNA Injection—Female Xenopus
laevis (Xenopus I, Ann Arbor, MI or Nasco, Fort Atkinson,WI)
were anesthetized using 0.2% tricaine methanesulfonate (MS-
222) (Sigma or Nasco). Ovarian lobes were surgically removed
from the frogs and placed in an incubation solution that con-
sisted of 82.5 mMNaCl, 2.5 mM KCl, 1 mMMgCl2, 1 mM CaCl2,
1mMNa2HPO4, 0.6mM theophylline, 2.5mM sodium pyruvate,
5mMHEPES, 50mg/ml gentamycin, 50 units/ml penicillin, and
50 g/ml streptomycin, pH 7.5. The lobes were cut into small
pieces and digestedwith 0.08Wünsch units/ml Liberase Blend-
zyme 3 (Roche Applied Science) with constant stirring at room
FIGURE 1. Construction of nAChR 3 subunit chimeras. A, alignment of nAChR h3 and m3 subunit protein sequences. Amino acid sequences of nAChR h3
(accession number NP_000740.1) andm3 subunits (accession number AAL75573.1) retrieved from GenBankTM were aligned using protein BLAST. AA numbering
beginsat thetranslationstartmethionine. Identical residuesbetweenhumanandmousenAChR3subunitsare indicatedbyadash (-).Putative loopregions (A,B,and
C in theprimary face andD, E, andF in the complementary face), TMdomains (I, II, III, and IV), andTM II 9 and13 aminoacid residues inhumanandmousenAChR3
subunits are identified. nAChR m3 subunit residues (Gln94, Glu101, Asn107, Ser144, Ser148, Asp221, and Phe223) given prime attention in mutagenesis studies are
underlinedand inboldface. Anupwardarrow (1) indicates junctions for chimeric subunits and the restriction sitesused for constructionof chimericmouse/human3
subunits.Colons (:) belowsequences indicate conserved residues.B, schematicdiagramsof chimericnAChR3 subunits. Chimericmouse/humannAChR3 subunits
with orwithout V9Smutations in their respective TM IIwere constructed. The 273rdAA in nAChRh3 subunit or the 279thAA in nAChRm3 subunit is a valine and
is notedas the9AA inTM II.N, N-terminal domain; I, II, III, or IV, respective TMdomains; cyto-loop, cytoplasmic loop;C, C terminus.Numbers inbrackets are the regions
of the indicated subunits that are used for construction ofmouse/human3 chimeric subunits.
Effects of3 Subunits onMouse6*-nAChR Function
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temperature for 1.5–2 h. The dispersed oocytes were thor-
oughly rinsed with incubation solution. Stage VI oocytes were
selected and incubated at 16 °C before injection. Micropipettes
used for injection were pulled from borosilicate glass (Drum-
mond Scientific, Broomall, PA) using a Sutter P87 or P1000
horizontal puller (Sutter Instrument Co., Novato, CA), and the
tips were broken with forceps to 40 m in diameter. cRNAs
were drawn up into the micropipette and injected into oocytes
using a Nanoject or Nanoject II microinjection system (Drum-
mond Scientific) at a total volume of 69 or 138 nl.
Oocyte Electrophysiology—Two to 5 days after injection,
oocytes were placed in a small volume chamber and continu-
ously perfused with OR2. The chamber was grounded through
an agarose bridge. The oocytes were voltage-clamped at 70
mV (unless otherwise noted) to measure agonist- or antago-
nist-induced currents using Axoclamp 900A and pClamp 10.2
software (Axon Instruments/Molecular Devices, Sunnyvale,
CA). The current signal was low pass-filtered at 10 Hz with the
built-in low pass Bessel filter in the Axoclamp 900A and digi-
tized at 20 Hz with Axon Digidata1440A and pClamp10. Elec-
trodes contained 3 M KCl and had a resistance of 1–2 megao-
hms. Drugs (agonists and antagonists) were prepared daily in
bath solution. Drug was applied using a Valvelink 8.2 perfusion
system (AutoMate Scientific, Berkeley, CA). Atropine (1 M)
was always co-applied for ACh-based recordings to eliminate
muscarinic acetylcholine receptor responses. nAChR 3 con-
structs were tested individually or in batches as they became
available to get an estimate of their effect on the function of
6*-nAChRs. Then, for the purpose of comparison, electro-
physiological recordings were performed in a given day in a
given batch of oocytes following the same order of injections.
Hence data points in a figure panel were obtained under similar
experimental conditions.
Experimental Controls—Injection of water or empty vector
(used as two forms of negative controls) or of cRNA corre-
sponding to one subunit alone or pairwise combinations of
nAChR 3, 3V9S, 3V13S, or other forms of 3 subunits with
either an 6 or other forms of 6 or 4 subunit (7–46 ng of
total cRNA) did not result in the expression of functional
nAChRs. Current responses to 100 M nicotine or ACh were
less than 5–10 nA (data not shown).
Data Analyses—Raw data were collected and processed in
part using pClamp 10.2 (Molecular Devices) and a spreadsheet
(Excel, Microsoft, Bellevue, WA) using peak current ampli-
tudes as measures of functional nAChR expression, and results
were pooled across experiments (mean S.E. for data from at
least three oocytes). In some cases, mean peak current ampli-
tudes in response to a single concentration of an agonist were
compared across different subunit combinations. However,
assessment of true Imax values for different nAChR subunit
combinations required assessment based on more complete
concentration-response relationships in which mean peak cur-
rent amplitudes at specified ligand concentrations were fit to
the Hill equation or its variants using Prism 4 (GraphPad Soft-
ware, San Diego, CA). F-tests (p  0.05 to define statistical
significance) were carried out to compare the best fit values
of log molar EC50 values across specific nAChR subunit
combinations.
There are limitations in the ability to compare levels of func-
tional nAChR expression even though we injected similar
amounts of RNA for all constructs. This is because expression
levels assessed as peak current amplitudes are affected by
batch-to-batch variation in oocytes, time between cRNA injec-
tion and recording, and subunit combination-specific parame-
ters, such as open probability (influenced by gating rate con-
stants and rates and extents of desensitization), single channel
conductance, assembly efficiency, and efficiency of receptor
trafficking to the cell surface (39). We made no attempt to
measure or control for subunit combination-specific effects,
but whenever preliminary studies revealed possible differences
in peak current amplitudes, findings were further confirmed
across different subunit combinations using the same batch of
oocytes and the same time between cRNA injection and record-
ing (15, 19, 30, 38). Therefore peak current amplitudes shown
for representative traces in some figures, pooled data from lim-
ited sets of studies, andmean peak current amplitudes across all
studies for a given combination of subunits given in tables or
figures sometimes differ. However, when we make statements
about results comparing ligand potencies and efficacies across
subunit combinations, the observations are clear, significant,
and in agreement whether for pooled data or for results from
smaller sets of studies (one-way analyses of variance followed
by Tukey’s multiple comparison tests).
RESULTS
Previously (15) we have shown that coexpression of WT
nAChR 6 and 2 subunits alone or in combination with 3 or
3V9S subunits in oocytes, all from a single species (human or
mouse), did not yield consistent and reproducible current
responses to nicotinic agonists. However, under similar experi-
mental conditions,wewere able to show that coexpressionofm6
subunits, instead of h6 subunits, with h2 and h3V9S subunits
led to expression of functional hybrid m6h2h3V9S-nAChRs
(15). Also, hybrid m6h4h3-nAChRs were fully func-
tional, although there was no function for h6h4h3- or
m6m4m3-nAChRs (15). These studies were carried out
by injecting 1–6 ng of cRNAs for each subunit into
oocytes. In continuation of our earlier efforts, in this study,
we substituted human 3 subunits for mouse 3 subunits.
Initially we injected about3.5 ng of cRNAs for each nAChR
subunit to express hybrid nAChRs, but later we increased
amounts injected to 23 ng for each subunit to emulate the
approach taken by Kuryatov et al. (14) to express functional
human 64*-nAChRs.
Incorporation of nAChR h3, h3V9S, or h3V13S Subunits
Potentiates m6m4*-nAChR Function—Coexpression with
WT h3 subunits significantly (p 0.05) potentiated ACh- or
nicotine-induced current responses of m6m4-nAChRs (Fig.
2 and Table 2). Also, coexpression with nAChR h3V9S or
h3V13S subunits increased (p  0.05) the current responses
further (Fig. 2 and Table 2). The increase in agonist sensitivities
and in peak current amplitudes indicate thatWT h3 subunits
incorporate into at least some complexes containing m6 and
m4 subunits and these effects are most likely due to higher
levels of functional receptor expression.Moreover, whereas not
all oocytes expressing m6 and m4 subunits yield functional
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responses to nicotinic agonists, almost all oocytes expressing
nAChR m6, m4, and h3 subunits produced functional
responses, suggesting that nAChR h3 subunits facilitate for-
mation of functional, trinary (containing three kinds of sub-
units) nAChRs.
Spontaneously Opening m6m4h3V9S- or m6m4h3V13S-
nAChRs Are Sensitive to Blockade by Atropine—Atropine (1
M) was always co-applied for ACh-based recordings to elimi-
nate muscarinic acetylcholine receptor responses. Because
atropine at higher concentrations also can interact with differ-
ent nAChR subtypes (15, 40, 41), initially as a simple control, we
assessed the effects of atropine at different concentrations
alone on all receptor combinations studied. Atropine alone did
not produce any effect when assessed using oocytes expressing
any combination ofWT nAChR subunits (data not shown), but
it reversibly produced outward currents when applied to
oocytes expressing receptors containing 3V9S or 3V13S sub-
units. The concentration-dependent effects of atropine were
FIGURE 2. Concentration-dependent effects of agonist exposure on current responses in oocytes expressing m6m4*-nAChRs. A, representative
traces are shown for inward currents in oocytes held at70mV responding to application at the indicated concentrations of ACh (shownwith the duration of
agonist exposure as black bars above the traces) and expressing nAChRm6 andm4 subunits alone (panel i) or in the additional presence of wild-type h3
(panel ii) or h3V9S (panel iii) subunits. Calibration bars are for 60-, 200-, or 500-nA currents (vertical) and 10 s (horizontal). Results for these and other studies
averaged across experiments were used to produce agonist- or antagonist-induced concentration-response curves (ordinate, mean normalized currentS.E.
(error bars);abscissa, ligand concentration in logM) for responses toACh (B), nicotine (C), or atropine (D) for oocytes expressingnAChRm6 andm4 subunits
alone (E) or in the additional presence of h3 (f), h3V9S (●), or h3V13S (‚) subunits as indicated. Leftward shifts in agonist concentration-response curves
are evident for functional nAChR containing h3, h3V9S, or h3V13S subunits (p 0.0001;2-,717-, and418-fold, respectively, for ACh EC50 values and
6-,605-, and 217-fold, respectively, for nicotine EC50 values relative to the respective agonist EC50 values for activation of m6m4-nAChR function). See
Table 2 for parameters.
TABLE 2
Parameters for drug action at hybrid h6h4*- or m6m4*-nAChRs
Potencies (micromolar EC50 or IC50 values with 95% confidence intervals (CI)), Hill coefficients (nH S.E.), mean S.E. efficacies (Imax in nA), and concentrations (conc.)
where maximal peak current amplitudes (Imax) are achieved (M) are provided for the indicated agonist (ACh or nicotine) or antagonist (atropine) acting at nAChR
composed of the indicated subunits derived from the specified species and from the indicated number of independent experiments (n) based on studies as shown in Fig. 2.
1 indicates a significant (p 0.05) increase in potency or efficacy of the specified agonist at the indicated nAChR subtype relative to nAChRupon expression in the presence
of the indicated wild-type or mutant 3 subunit instead of in the absence of a 3 subunit, Œ indicates a significant increase in specified agonist potency or efficacy at the
indicated nAChR subtype upon substitution of amutant for awild-type3 subunit relative to nAChR containing the same subunits in the presence of wild-type3 subunits,
and‚ orƒ indicates a significant increase or decrease, respectively, in potency or efficacy of the specified agonist or antagonist at the indicated nAChR subtype containing
3V13S instead of 3V9S subunits.
Drug
nAChR subunit
combinations
Potency Peak response
n EC50 or IC50 (95% CI) nH S.E. n Mean ImaxS.E. Imax conc.
M nA M
ACh m6m4a 3 38 (25–58) 0.72 0.09 3 65 25 1000
m6m4 h3 4 18 (12–28)1 0.62 0.07 4 358 1281 100
m6m4 h3V9S 4 0.05 (0.03–0.11)1Œ 0.45 0.07 3 3379 1891Œ 1001Œ
m6m4 h3V13S 4 0.09 (0.05–0.16)1Œ 0.64 0.1 4 2989 431Œ 1001Œ
Nicotine m6m4a 3 24 (14–50) 0.65 0.13 5 27 7 1000
m6m4 h3 4 4.5 (2.5–8.3)1 0.78 0.16 4 212 51 1001
m6m4 h3V9S 6 0.04 (0.03–0.06)1Œ 0.84 0.10 7 2884 3331Œ 101Œ
m6m4 h3V13S 7 0.12 (0.08–0.17)1Œƒ 0.79 0.1 8 2783 6221Œ 101Œ
Atropine m6m4 h3V9S 3 16 (1–241) 1.40 2.4 3 140.8 13.44 1000
m6m4 h3V13S 3 17 (4.8–58) 0.90 0.46 3 512.6 28.87 ‚ 1000
a Data from Ref. 15.
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defined in terms of IC50 values for half-maximal blockade of
spontaneous function, which for m6m4h3V9S- and
m6m4h3V13S-nAChRs were 16 and 17 M, respectively
(Fig. 2 and Table 2). It is estimated, based on comparisons of
atropine-induced outward current peak amplitudes with the
sum of those currents plus inward currents induced by fully
efficacious concentrations of nicotine or ACh, that more than
4–16% of these receptors are spontaneously open at any one
time.
Function of m6m2*-nAChRs Is Potentiated by Coexpres-
sion with nAChR m3V9S Subunits and Is Yet Higher upon
Coexpression with h3V9S Instead ofm3V9S Subunits—Coex-
pression of h3 or h3V9S subunits in oocytes also expressing
m6 and m2 subunits did not lead to reproducible current
responses to ACh or nicotine whenever they were expressed
using 3 ng of cRNA for each subunit (data not shown). We
decided to inject higher amounts of cRNA for each subunit (simi-
lar to the approach taken by Kuryatov et al. (14) to express
h6h4- or h6h4h3-nAChRs) to see whether that would
influence the functional expression of m6m2*-nAChRs.
Current responses to nicotine from oocytes expressing
m6m2m3V9S-nAChRs increased with injection of increased
amounts of cRNA for each subunit (Fig. 3).However, at the largest
amount of cRNA for each subunit injected (23 ng), there was
no functional expression of m6m2m3- or m6m2h3-
nAChRs. Nonetheless, oocytes expressing m6m2h3V9S-
nAChRs yielded higher peak current responses (589  121 ver-
sus 66  7 nA; 9-fold; p  0.05) than those expressing
m6m2m3V9S-nAChRs (Fig. 3). Oocytes expressing
m6m2h3V9S-nAChRs, but not m6m2m3V9S-nAChRs,
cultured for prolonged times produced some outward reversible
currents in response to atropine (data not shown). The EC50 value
fornicotine foractivationofm6m2h3V9S-nAChRs is0.08M.
Incorporation of Chimeric Mouse/Human 3 Subunits into
Mouse 62*- and 64*-nAChRs—We extended our studies
to work using chimeric mouse/human nAChR 3 subunits to
understand the molecular bases for the differential effect of
m3 andh3 subunits onm6*-nAChR function.We first con-
structed the BglII site-based nAChR chimeric subunit m3(1–
329)/h3(324–458). We injected 23 ng of cRNA for each
subunitaswedid forexpressionofm6m2(m3V9Sorh3V9S)-
nAChRs to express m6m4-, m6m4m3-, m6m4h3-, or
m6m4m3(1–329)/h3(324–458)-nAChRs. Initial assess-
ments indicated that all these nAChRs were functional, but the
current responses from oocytes expressing m6m4m3(1–
329)/h3(324–458)-nAChRs were similar to those from
oocytes expressing m6m4-nAChRs and lower than those
elicited from oocytes expressing m6m4h3-nAChRs (see
Fig. 4B). Coexpression of this chimeric subunit with m6 and
m2 subunits did not produce any detectable functional
nAChR. These results prompted us to construct two additional
chimeras that either increased or reduced the length of the h3
subunit contribution to mouse/human 3 subunit chimeras.
This led to construction of chimeric m3(1–187)/h3(182–
458) (SalI restriction site-based) and m3(1–375)/h3(370–
458) (BsiWI restriction site-based) subunits. All three chimeras
were assessed in parallel for their effects on m6m2*- or
m6m4*-nAChRs.
Coexpression of chimeric mouse/human nAChR subunits
(i.e. m3(1–187)/h3(182–458), m3(1–329)/h3(324–458),
or m3(1–375)/h3(370–458)) with nAChR m6 and m2
subunits in oocytes did not result in detectable nAChR function
(data not shown). However, these chimeric subunits coex-
pressed with m6 and m4 subunits yielded minimally func-
tional nAChRs. Results indicated that peak current responses
of m6m4[m3(1–187)/h3(182–458)]-, m6m4[m3(1–
329)/h3(324–458)]-, or m6m4[m3(1–375)/h3(370–
458)]-nAChRs are similar (p 	 0.05) to those of m6m4-
(50  13 nA; 1000 M nicotine) or m6m4m3-nAChRs
(85 15 nA; 100 M nicotine) but lower (p 0.05) than those
of m6m4h3-nAChRs (410 88 nA; 100 M nicotine) (Fig.
4B).
Incorporation of Gain-of-function Chimeric Mouse/Human
nAChR 3 Subunits into Mouse 62*- and 64*-nAChRs—
To evaluate whether the chimeric nAChR m3/h3 subunits
are truly participating in m6*-nAChR formation, we assessed
the incorporation of gain-of-function m3(1–187)/h3(182–
458)V9S, m3(1–329)V9S/h3(324–458), or m3(1–375)V9S/
h3(370–458) subunits into m6m2*- and m6m4*-
nAChRs. Coexpression of these gain-of-function chimeric
nAChR subunits with m6 and m2 subunits in oocytes
resulted in the production of functional nAChRs (Fig. 4A). Cur-
rent responses from oocytes expressing chimeric m6m2*-
nAChRs progressively decreased when coexpressed with chi-
FIGURE 3.Effects of agonist exposureon current responses in oocytes expressingm6m2(m3V9S or h3V9S)-nAChRs.A, current responses (mean
S.E. (error bars); nA) to 100 M nicotine obtained on the 5th day after injection from oocytes (n  3–6) voltage-clamped at 70 mV and expressing
m6m2m3V9S orm6m2hV9-nAChRs. Oocyteswere injectedwith the indicated amount (ng) of cRNA for each subunit. B, concentration-response curve
for responses to nicotine (ordinate, mean normalized inward current S.E. (error bars); abscissa, ligand concentration in log M) for oocytes expressing
m6m2h3V9S-nAChRs. *, p 0.05.
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meric 3 subunits containing shorter N-terminal segments
from the mouse 3 subunit. For example, m6m2[m3(1–
187)/h3(182–458)V9S]-nAChRs were least responsive to nic-
otine. This suggested that a combination of m3 subunit
domains and residues contributes to impeded functional
expression of m6m2*-nAChRs.
Incorporation of m3(1–187)/h3(182–458)V273S, m3(1–
329)V279S/h3(324–458), or m3(1–375)V279S/h3(370–458)
subunits into m6m4-nAChRs yielded functional nAChRs
(Fig. 4C). Peak current responses from oocytes expressing
m6m4[m3(1–329)V279S/h3(324–458)]-nAChRs (1505
353 nA) were similar (p	 0.05) to those of m6m4m3V279S-
or m6m4h3V273S-nAChRs. However, oocytes expressing
m6m4[m3(1–187)/h3(182–458)V273S]- (148 13 nA) or
m6m4[m3(1–375)V279S/h3(370–458)]-nAChRs (122 
33 nA) yielded much lower (p  0.001) peak current
responses than those expressing either m6m4m3V279S-
or m6m4h3V273S-nAChRs. Although the presence of h3
subunit residues from TM III through the large, second cyto-
plasmic domain to the C terminus seems somehow to quell
such an effect, this again suggested that a combination of m3
subunit domains and residues contributes to reduced func-
tional expression of m6m4*-nAChRs. However, strongest
implicationswere that the extracellularN-terminal domainwas
involved.
N-terminal AA Residues in the nAChR m3 Subunit That
Influence the Function of Mouse 62*- and 64*-nAChRs—
Because effects on m6m2*- and m6m4*-nAChR function
were most extreme in chimeras containing extracellular N-ter-
minal domains from the m3 subunit, we focused on this
region and on residues that differ between h3 and m3 sub-
units. For all nAChR subunits, there is a “primary” or () face
and a “complementary” or () face where subunit extracellular
N-terminal domains interact, forming a subunit interface.
Interface interactions are critical for subunits to form dimers
and for dimers to join with a single subunit to close the penta-
meric assembly. Interfaces involving the primary face of spe-
cific  subunits and the complementary face of specific  sub-
units also are known to contain agonist binding pockets,
occupancy of which leads to channel opening and where com-
petitive antagonists also bind to affect function (the  subunit
was designated as that providing the primary face because itwas
initially thought that agonist binding sites resided solely within
 subunits). nAChR biologists have identified several loops at
turns in -strands that criss-cross subunit extracellular
domains as in a woven basket. So-called loop 2-3 (named so
because the loop is formed at the tip of a turn between strands
2 and3) and loopsD, E, and F are evident frommodeling and
structural studies to be on the complementary face of a given
subunit, whereas loops A, B, and C are on the primary face.
Loops A–F appear to be engaged in ligand recognition. For
site-directed mutagenesis studies, we focused on some of the
very few residues that differ between h3 and m3 subunits,
AAs Gln94, Glu101, and Asn107 in the 2-3 loop; AAs Ser144
and Ser148 in putative loop E, and AAs Glu221 and Phe223 in
putative loop C, to determine roles in functional expression of
m6m2*- and m6m4*-nAChRs (Fig. 1A). Residues in the
nAChR m3 subunit were mutated to their counterparts in
the nAChR h3 subunit alone or in specific combinations
(i.e. m3(Q94H), m3(E101D), m3(N107H), m3(Q94H/
E101D), m3(Q94H/N107H), m3(S144N/S148V), m3(E221D),
andm3(E221D/F223V)) (Fig. 5).
AA Substitutions in the 2-3 Loop of nAChR m3
Subunit Influence the Current Responses of m6m2*- or
m6m4*-nAChRs—Coexpression of nAChR m3 subunit
point mutants (Q94H, E101D, or N107H) or double mutants
(Q94H/E101DorQ94H/N107H) in oocyteswithm6 andm2
subunits did not lead to production of functional nAChR.How-
ever, these mutant subunits harboring the V9S mutation
in their respective TM II domains (i.e. m3(Q94H)V9S,
m3(E101D)V9S, m3(N107H)V9S, m3(Q94H/E101D)V9S,
or m3(Q94H/N107H)V9S) upon coexpression with m6 and
FIGURE 4. Effects of chimeric mouse/human or gain-of-function chimeric mouse/human nAChR 3 subunits on functional responsiveness of m6*-
nAChRs. A–C, mean S.E. (error bars) peak inward current responses upon exposure to 100 or 1000 M nicotine (5-s exposure; ordinate) from oocytes (n
3–10) voltage-clamped at70 mV and heterologously expressing m6m2*- (A) or m6m4*-nAChRs (B and C) in the presence of the indicated chimeric
nAChR 3 subunits. Note that m6m4-nAChRs reach Imax at 1000 M nicotine. The largest amplitude responses to nicotine were observed when h3 or
h3V9S subunitswerepresent inm6mh2*- orm6mh4*-nAChRs. Current responseswere comparedusingone-way analyses of variancewith Tukey’s post
hoc comparison. Groups with different letters (a, b, and c) are significantly (p 0.05) different. **, p 0.01; ***, p 0.001.
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m2 subunits in oocytes and responding to application of 100
Mnicotine produced peak current responses of 110 25, 68
9, 26 7, 78 10, or 99 12 nA, respectively (Fig. 5A, panel i).
The peak current responses of m6m2[m3(Q94H)V9S]-,
m6m2[m3(E101D)V9S]-, m6m2[m3(N107H)V9S]-,
m6m2[m3(Q94H/E101D)V9S]-, or m6m2[m3(Q94H/
N107H)V9S]-nAChRs did not differ (p  0.05) from those of
m6m2m3V9S-nAChRs (73 12 nA).
Oocytes expressingm6andm4 subunits aloneor in theaddi-
tional presence of m3(Q94H), m3(E101D), m3(N107H),
m3(Q94H/E101D), or m3(Q94H/N107H) subunits produced
functional nAChRs (Fig. 5B, panel i). Peak current responses of
m6m4m3-nAChRs (57  13 versus 113  18 nA) were
increased (2-fold; p 0.05) as a result of Q94H/N107H double
substitution in the nAChR m3 subunit. Also, the current
responses of m6m4m3(Q94H/N107H)-nAChRs were higher
(3-fold; p 0.05) than those of m6m4-nAChRs (39 7 nA).
AA Substitutions in Loop E of the nAChRm3 Subunit Influ-
ence the Function of m6m2*- or m6m4*-nAChRs—Coex-
pression of gain-of-function nAChR m3(S144N/S148V)V9S
subunits, but not nAChR m3(S144N/S148V) subunits, in
oocytes with m6 and m2 subunits resulted in production of
functional nAChRs.Current responsesofm6m2[m3(S144N/
S148V)V9S]-nAChRs to 100 M nicotine (109  31 nA) were
not different (p  0.05) from those of m6m2m3V9S-
nAChRs (73  12 nA) (Fig. 5Aii). Peak current responses of
m6m4m3-nAChRs were increased (266  27 versus 85 
15 nA; 2.5-fold; p  0.05) as a result of the S144N/S148V
double mutation in the nAChR m3 subunit (Fig. 5Bii). EC50
values for nicotine at m6m4h3-, m6m4m3-, and
FIGURE 5. Effects of nAChRm3 subunit amino acid substitutions on the current responses of m6*-nAChRs. A and B, current responses (mean S.E.
(error bars)) from oocytes (n  3–6) (voltage-clamped at 70 mV) responding to the application of 100 or 1000 M nicotine (5-s exposure; ordinate) were
measured from m6m2*- (A) or m6m4*-nAChRs (B) harboring WT, mutant, or gain-of-function m3-, m3(Q94H)-, m3(E101D)-, m3(E107H)-,
m3(Q94H/E101D)-, orm3(Q94H/N107H)-nAChR subunits (panel i);WT,mutant, or gain-of-functionm3-orm3(S144N/S148V)-nAChR subunits (panel ii); or
WT,mutant, or gain-of-functionm3-,m3(E221D)-, orm3(E221D/F223V)-nAChR subunits (panel iii). Current responseswere comparedusingStudent’s t test
(two-tailed) or one-way analyses of variance (with Tukey’s post hoc comparison). Groups with different letters (a and b) are significantly (p 0.05) different. *,
p 0.05; **, p 0.01; ***, p 0.001.
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m6m4m3(S144V/S148V)-nAChRs (i.e. 4.5, 6.6, and 10M,
respectively; Fig. 6 and Table 3) were essentially the same (p	
0.05).
AA Substitutions in Loop C of in the nAChR m3 Subunit
Influence the Function of m6m2* or m6m4*-nAChRs—
Oocytes expressing m6m2[m3(E221D)V9S]- (155  38
nA) or m6m2[m3(E221D/F223V)V9S] (193  18 nA)-
nAChRs elicited higher (2–3-fold; p  0.05) peak currents
in response to 100 M nicotine than those expressing
m6m2m3V9S-nAChRs (73  12 nA; Fig. 5Aiii). However,
coexpression of nAChR m3(E221D) or m3(E221D/F223V)
subunits in oocytes with m6 and m2 subunits did not result
in expression of functional nAChR. Substitution of nAChR
m3(E221D) (199  34 nA; 2-fold) or m3(E221D/F223V)
(307  32 nA; 6-fold) subunits for m3 subunit increased
(p  0.05) the current responses of m6m4m3-nAChRs
(85 15 nA (Fig. 5Biii)). However, EC50 values for nicotine at
m6m4m3- (6.6 M) or m6m4h3 (4.5 M)-nAChRs
were not altered (p 	 0.05) when m3(E221D) (4 M) or
m3(E221D/F223V) (6.5 M) subunits were substituted for
m3 subunits (Fig. 6 and Table 3).
AA Substitutions in Loop C of nAChR m3 Subunit Also Influ-
ence Function of m6(L9S or V13S)m2*-nAChRs—Previously,
we could not detect functional expression of m6L9Sm2-
or m6V13Sm2-nAChRs or of m6L9Sm2m3- or
m6V13Sm2h3-nAChRs in oocytes (38). Upon increasing
the amount of cRNA injected for each subunit to23 ng, there
was emergence of functional m6(L9S or V13S)m2m3-
nAChRs, but not m6(L9S or V13S)m2-nAChRs, in oocytes.
However, nicotine-elicited (100 M) peak current responses
from oocytes expressing m6V13Sm2m3-nAChRs were
higher (70 18 versus 9 1 nA;8-fold; p 0.05) than those
expressing m6L9Sm2m3-nAChRs (Fig. 7).
We also assessed whether substitutions of AA residues in
loop C of the nAChR m3 subunit would increase the peak
current responses of m6L9Sm2*- or m6V13Sm2*-
nAChRs. Nicotine-elicited (100 M) peak current responses
from oocytes expressing m6L9Sm2m3- (9 1 versus 17
2 nA) or m6V13Sm2m3 (70  18 versus 170  28 nA)-
nAChRs were increased (p 0.05) as a result of E221D/F223V
substitution in the nAChRm3 subunit. Also, oocytes express-
ingm6V13Sm2m3(E221D)-nAChRs (162 32 nA) yielded
higher peak current (p 0.05) in response to 100 M nicotine
FIGURE 6. Effects of nAChRm3 subunit amino acid substitutions on nic-
otine sensitivities of m6m4*-nAChRs. Concentration-response curves
(ordinate,meannormalized currentS.E. (error bars);abscissa, ligandconcen-
tration in logM) are shown for responses to nicotine for oocytes expressing
nAChRm6 andm4 subunits alone (●) or in the additional presence of h3
(*), m3 (
), h3(S144N/S148V) (E), h3(E221D) (), or h3(E221D/F223V)
(f) subunits as indicated. Leftward shifts in agonist concentration-response
curves are evident for functional nAChRs containing h3, m3, h3(S144N/
S148V), h3(E221D), h3(E221D/F223V), or h3(E347Q/R361K) subunits. See
Table 3 for parameters.
FIGURE 7. Effects of nAChRm3 subunit loop C amino acid substitutions
on functional responsiveness of m6(L9S or V13S)m2*-nAChRs.Mean
S.E. (error bars) peak inward current responses upon exposure to 100 M nic-
otine (5-s exposure;ordinate)weremeasured fromoocytes (n3–6) voltage-
clampedat70mVandheterologously expressingm6L9S,m2-plusm3-,
m3(E221D)-, or m3(E221D/F223V)- (A) or m6V13S-, m2- plus m3-,
m3(E221D)-, or m3(E221D/F223V)-nAChR subunits (B). Current responses
were compared using one-way analyses of variance (with Tukey’s post hoc
comparison). *, p 0.05; **, p 0.01.
TABLE 3
Parameters for nicotine action at nAChRs containing m6 andm3mutant subunits
Potencies (micromolar EC50 values with 95% confidence intervals (CI)), Hill coefficients (nH S.E.), mean S.E. efficacies (Imax in nA), and concentrations (conc.) where
maximal peak current amplitudes (Imax) are achieved (M) are provided for nicotine acting at mouse nAChR composed of the indicated subunits and from the indicated
number of independent experiments (n) based on studies as shown in Fig. 6.1 indicates a significant (p 0.05) increase in the indicated parameter at the indicated nAChR
subtype relative to wild-type m6m4-nAChR, and Œ indicates a significant (p  0.05) increase in the indicated parameter at the indicated nAChR subtype relative to
wild-type m6m4m3-nAChR.
Potency Peak response
nAChR subunit combinations n EC50 (95% CI) nH S.E. Mean ImaxS.E. Imax conc.
M nA M
m6m4 6 23 (15–37) 0.8 0.13 50 13 1000
m6m4m3 3 6.6 (5.1–8.5)1 1.1 0.12 85 15 1001
m6m4m3(S144N/S148V) 5 10 (8.2–13)1 1.2 0.18 266 271Œ 1001
m6m4m3(E221D) 5 4 (2.3–7.2)1 0.8 0.18 199 341Œ 1001
m6m4m3(E221D/F223V) 5 6.5 (5.1–8.2)1 1 0.11 307 321Œ 1001
Effects of3 Subunits onMouse6*-nAChR Function
OCTOBER 10, 2014•VOLUME 289•NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 28347
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
than those expressing m6V13Sm2m3-nAChRs. These
results confirm the previous findings that TM II 13 valine-to-
serinemutations in them6 subunit aremore capable of attrib-
uting gain of function to m6*-nAChRs than the TM II 9 leu-
cine-to-serine mutation (38).
DISCUSSION
Functional heterologous expression of human or mouse 6*-
nAChRs has been difficult. Various approaches have been under-
taken to circumvent this situation for human6*-nAChRs (14, 15,
19, 22, 31, 38, 42). There is hardly any focus on heterologous
expression of functional mouse 6*-nAChRs, although they are
known to be physiologically important (3, 8, 10, 12, 43–45). Our
initial studies, using1–6ng of cRNA for each subunit, indicated
that mouse 64-nAChRs expressed in oocytes are minimally
functional (15). Although there was no emergence of functional
mouse 643-nAChRs in oocytes, mouse 643V9S-nAChRs
in oocytes were highly functional (15). Functional m6m2-,
m6m2m3-, or m6m2m3V9S-nAChRs or m6L9Sm2-,
m6L9Sm2m3-, m6V13Sm2-, or m6V13Sm2m3-
nAChRsalsowerenotdetected inoocytes (15, 38). Incontinuation
of these studies, here we used various approaches to produce or
enhance the functional expression of mouse 6*-nAChRs.
We noticed that upon substitution of nAChR h3 sub-
units for nAChR m3 subunits highly functional hybrid
m6m4h3-nAChRs were produced in oocytes. We also
noticed that functional m6m4m3-nAChRs were formed in
oocytes when they were expressed using an injection of rela-
tively larger amounts of cRNAs (23 ng) for each subunit. The
peak current responses of these m6m4m3-nAChRs
were nonetheless severalfold lower than those of hybrid
m6m4h3-nAChRs. Similar to previous observations (15),
whether using relatively lower or higher amounts of injected
cRNA for each subunit, functional m6m2-, m6m2m3-,
or m6m2h3-nAChRs were not detected in oocytes. How-
ever, upon increasing the amount of cRNA injected for each
subunit, minimally functional m6m2m3V9S- or robustly
functional m6m2h3V9S-nAChRs emerged on cell sur-
faces. Additionally, m6m4*-nAChRs harboring h3V9S or
h3V13S subunits showed gain of function similar to those of
m6m4m3V9S- orm6m4m3V13S-nAChRs (15). There-
fore, incorporation of h3 or m3 subunits into m6m4*-
nAChRs is evident because it had a potentiation effect. These
results also suggest that these WT 3 subunits must be facili-
tating assembly of functional receptors. Potentiation of agonist
sensitivity and levels of functional responses also indicate that
therewas incorporation ofmutant h3V9S orm3V9S subunits
into m6m4*- or m6m2*-nAChRs with further facilitation
of functional receptor expression, increased frequency of ago-
nist-gated channel opening, or both. These results also are
indicative of efficient incorporation of h3 subunits, but not
that ofm3 subunits, into assemblies ofm6 andm4 subunits
or of m6 and m2 subunits.
Our results confirm that trinary complexes involving m6
plus m2 or m6 plus m4 subunits are formed. The observa-
tion that functional m6m4*-nAChRs, but not m6m2*-
nAChRs, were formed whenever oocytes were injected with
higher amount of cRNAs is consistent with such observations
made in studies of expression of human6*-nAChRs in oocytes
(14). We also extended this strategy to ensure expression of
functional m6m2m3V9S- or m6m2h3V9S-nAChRs.
The need for elevated subunit abundance in oocytes for forma-
tion of cell surface, functional 6*-nAChRs is in contrast to the
relative ease of expression of functional WT 24-, 32-,
34-, 42-, or 44-nAChRs or hybrid m6h4h3- or
m6h2h3V9S-nAChRs in oocytes using1–2 ng of cRNAs
for each subunit (27, 30). This also suggests that differences in
features or AA sequence between m3 and h3 subunits
accounts for increased efficiency of subunit assembly to closure
of pentameric and functional m6*-nAChRs.
Transmembrane II 9 or 13 valine-to-serine mutants of h3
or m3 ((h3 or m3)(V9S or V13S)) subunits whenever coex-
pressedwithm6m4*-nAChRs almost always yielded oocytes
giving apparently outward current responses to atropine, indi-
cating integration of3 subunits intom6m4*-nAChRs. This
also indicates that these channels are opening spontaneously, a
feature commonly seen for receptors of the ligand-gated ion
channel family containing gain-of-function mutations (TM II
V9S or V13S) (15, 19, 38, 46). Effects of atropine at high con-
centrations reflect its open channel blocking ability, which is
seen for oocytes expressing m6m2h3V9S-nAChRs but not
m6m2m3V9S-nAChRs (data not shown).
Differences in amino acid composition between h3 and
m3 subunit extracellular N-terminal and second cytoplasmic
loop regions (e.g. as opposed to their nearly identical trans-
membrane domains) that influence effects on 6*-nAChR
function were revealed based on studies of chimeric nAChR
mouse/human 3 subunits or their gain-of-function variants.
The involvement of the NTD of 3 subunits in these effects
echoes previous findings that the NTD of h6 subunits influ-
ences assembly and function of human 63*-nAChRs (15, 19,
38).
The current site-directed mutagenesis studies indicate that
substitution ofm3 subunit AA residues in primary face loopC
with h3 subunit residues enhanced functional expression of
m6m2m3V9S-nAChRs. In addition, h3 subunit AA sub-
stitutions in complementary face 2-3 and E loops for resi-
dues in m3 subunits increased functional expression of
m6m4m3-nAChRs. These results are in agreement with
the previous observations that substitutions at extracellular
N-terminal loops influence functional expression of h6*-
nAChRs and other subtypes of nAChRs (15, 19, 38, 47).
The increased functional expression of m6*-nAChRs seen
upon AA substitution in m3 subunits must be due to some
combination of increases in efficiency of incorporation of sub-
units into receptor complexes, trafficking to the cell surface,
and/or preservation of cell surface receptors. nAChRm3 sub-
unit loop E residues Ser144 and Ser148 differ from Asn or Val
residues, respectively, in h3 subunits in side chain length and
possibility of engaging in glycosylation (Ser versus Asn) and
hydrophobicity (Ser versusVal) (48). nAChRm3 subunit loop
C residues Glu221 and Phe223 differ fromAsp or Val AAs in h3
subunits in side chain length (Glu versus Asp and Phe versus
Val) and to some degree in hydrophobicity (Phe versus Val).
These differences in AAs could influence interactions with
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adjacent (or distant?) 2, 4, or 6 subunits that are important
for m6m2*- and m6m4*-nAChR assembly (Fig. 8D).
2-3 or E loop residues in the negative () or complemen-
tary face of the m3 subunit would be involved in presumed
interactions with residues on the positive () or primary faces
of the neighboringm4 orm2 subunit, and loop C residues in
the positive () or primary face of the 3 subunit would be
involved in presumed interactions with residues on the nega-
tive () or complementary faces of the neighboring m6 sub-
unit in a complex that has the presumed arrangement of (3
or 3V9S):6:(2 or 4):6:(2 or 4) where
ligand binding pockets are thought to be located between the
primary () face of m6 and complementary () face of the
m2 or m4 subunits (i.e. 6:4 or 6:2) (Fig. 8). Ago-
nist binding is not expected occur at 3:(2 or 4) or 3:
6 subunit interfaces. However, recent evidence suggests that
interfaces involving subunits in the accessory subunit position
where the 3 subunit would be situated can engage in allosteric
or co-agonist effects (49–51). Residues in or equivalent to those
atm3 subunit positions 94, 101, 107, 144, 148, 221, and 223 are
FIGURE 8. Illustration of nAChR 3 subunit residues and its interfaces that are important in the function of m6*-nAChRs. A, sequence alignment of
nAChR 3 subunit proteins from several species. nAChR 3 protein sequences extracted from GenBank accession numbers NP_ 775304.1 (Mouse; Mus
musculus), NP_000740.1 (Human; Homo sapiens), NP_990143.1 (Chicken; Gallus gallus), NP_001080652.1 (Frog; X. laevis), NP_598281.1 (Rat; Rattus norvegicus),
NP_001029105.1 (Chimpanzee; Pan troglodytes), XP_599970.2 (Cow; Bos taurus), and NP_775394.1 (Zebrafish; Danio rerio) were aligned using ClustalW. B,
sequence alignment of mouse nAChR 3 subunit proteins. Mouse nAChR subunits were aligned using ClustalW. For both A and B, numbering begins at the
translation start methionine of the mouse nAChR 3 subunit protein and is shown in the N-terminal domain region of interest. Symbols below sequences
indicate fully (*), strongly (:), or weakly (.) conserved residues, and underlining in shaded face indicates numbered residues in nAChRm3 subunit targeted for
mutagenesis studies.C, a three-dimensionalmodel of theN-terminal domain ofmouse nAChR3 subunit. A three-dimensionalmodel of themouse nAChR3
subunit was generated based on the crystal structure of Torpedo muscle nAChR  subunit (Protein Data Bank code 2BG9:B). The N-terminal domain of the
nAChR m3 subunit possesses  strands that form a  sandwich and conforms to an immunoglobulin fold. AA residues in the 2-3 loop (Gln94 and Glu101),
loop E (Ser144 and Ser148), or loopC (Glu221 and Phe223) that positively influence the current responses ofm6*-nAChRs are identified. The figure displayedwas
drawn using the program Chimera. D, schematic illustration of the composition of mm4*-nAChRs. Adhering to the canonical rule of pentamer formation,
m6m4-nAChRs would be formed of three 6 and two 4 subunits (left) or two 6 and three 4 subunits (middle). In the eventm3 subunits are integrated
into m6m4*-nAChRs, they would substitute for the third m6 subunit in the first (left) configuration or the third m4 subunit in the second (middle)
configuration, occupyingwhat is labeledas the fifthposition (yellow). Agonist (AChornicotineandothers) binding sites at the interfacesbetween6andeither
2 or4 subunits are shown as ovals. Results from the current study (right) support the idea that the2-3 loop and loop E residues in the () face and/or loop
C residues in the () face (arrows) of them3 subunit are important in higher functional expression ofm6m4*-nAChRs.Mouse62*-nAChRswould attain
similar configurations, but the 2 subunit would substitute for the 4 subunit.
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conserved with those in rats but differ from those that are con-
servedwithin primates (human and chimp; Fig. 8A). Thesem3
subunit AAs also are unique across mouse nAChR subunits
(Fig. 8B). We have advanced the possibility that these residues
could affect efficiency of 6*-nAChR assembly (not altering
agonist potency but affecting peak current responses as for
m6*-nAChRs harboring m3(S144N/S148V), m3(E221D),
or m3(E221D/F223V) subunits). Another intriguing possibil-
ity is that these unique residues could allow formation of novel
classes of ligand binding sites at 2/4:3 or 3:6 subunit
interfaces that also could lead to changes in levels of receptor
function as for ligand occupancy of the 4:4 subunit interface
in low sensitivity 42*-nAChR (51).
Plenty of information is available on the role of primary face
loops (A, B, and C) from  subunits and complementary face
loops (D, E, and F) from  subunits that participate in ligand
binding largely from structural and/or mutagenesis studies of
muscle-type, 7-, or other nAChRs and from lower eukaryotic
and prokaryotic proteins structurally homologous to the extra-
cellular domain of nAChRs (52–54). Our results presented
here, for the first time, show that extracellular N-terminal
domain loops of the accessory subunit, 3, regulate the func-
tional expression of m6*-nAChRs. These results also provide
further evidence that nAChR 3 subunits not only form func-
tional receptors in combination with nAChR 6 subunits but
also can enhance their function by interacting with adjacent
subunits mediated by N-terminal loop residues. Current find-
ings lay a foundation for enhanced functional expression of
m6*-nAChRs that could facilitate the discovery and develop-
ment of nicotinic ligands that selectively interact with 6*-
nAChRs. These results could be useful to fuel and inform
emerging interest in 6 and 3 subunits and the receptors they
compose with specific reference to possible roles in locomo-
tion, reward and reinforcement behavior, schizophrenia, and
Parkinson disease (5, 6, 55).
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